Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Isolated Intraventricular Rosai-Dorfman Disease.

Patwardhan PP, Goel NA.

Asian J Neurosurg. 2018 Oct-Dec;13(4):1285-1287. doi: 10.4103/ajns.AJNS_134_18.

2.

Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma.

Patwardhan PP, Musi E, Schwartz GK.

Mol Cancer Ther. 2018 Nov;17(11):2329-2340. doi: 10.1158/1535-7163.MCT-18-0319. Epub 2018 Aug 30.

PMID:
30166401
3.

Targeted inhibition of glutaminase as a potential new approach for the treatment of NF1 associated soft tissue malignancies.

Sheikh TN, Patwardhan PP, Cremers S, Schwartz GK.

Oncotarget. 2017 Oct 6;8(55):94054-94068. doi: 10.18632/oncotarget.21573. eCollection 2017 Nov 7.

4.

Pure Uterine Lipoma: A Common Tumour at an Uncommon Site.

Patwardhan PP, Waghmare TP, Taware AC.

J Clin Diagn Res. 2017 May;11(5):ED34-ED35. doi: 10.7860/JCDR/2017/27479.9931. Epub 2017 May 1.

5.
6.

MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.

Slotkin EK, Patwardhan PP, Vasudeva SD, de Stanchina E, Tap WD, Schwartz GK.

Mol Cancer Ther. 2015 Feb;14(2):395-406. doi: 10.1158/1535-7163.MCT-14-0711. Epub 2014 Dec 17.

7.

Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.

Patwardhan PP, Surriga O, Beckman MJ, de Stanchina E, Dematteo RP, Tap WD, Schwartz GK.

Clin Cancer Res. 2014 Jun 15;20(12):3146-58. doi: 10.1158/1078-0432.CCR-13-2576. Epub 2014 Apr 9.

Supplemental Content

Loading ...
Support Center